Company intelligence / Profile preview

Liverna Therapeutics

Ownership: Private
Development stage: Phase 3

Overview

Liverna's lead program is an mRNA RSV vaccine that has received clinical trial approval in China and the U.S., with preclinical data showing significantly higher humoral and cellular immunity than international benchmarks. The company also has IND approvals/applications for other infectious disease vaccines and rare disease targets. Commercial-scale GMP manufacturing is established.

Therapeutic areas: OncologyEndocrinologyRare DiseasesInfectious Diseases
Modalities: mRNA-based drugsmRNA vaccineBiological products
Industry: Biotech

Drug pipeline

2 assets

RV021

Phase 3

Indications: Rabies

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Liverna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liverna Therapeutics.